Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$5.77 - $12.19 $844,410 - $1.78 Million
-146,345 Reduced 58.2%
105,089 $1.26 Million
Q3 2023

Nov 14, 2023

SELL
$6.27 - $8.15 $296,984 - $386,032
-47,366 Reduced 15.85%
251,434 $1.59 Million
Q2 2023

Aug 11, 2023

BUY
$6.63 - $9.9 $856,596 - $1.28 Million
129,200 Added 76.18%
298,800 $2.35 Million
Q1 2023

May 12, 2023

BUY
$5.72 - $7.91 $176,176 - $243,628
30,800 Added 22.19%
169,600 $1.17 Million
Q4 2022

Feb 13, 2023

SELL
$4.68 - $6.54 $587,283 - $820,691
-125,488 Reduced 47.48%
138,800 $884,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $541,178 - $1.22 Million
145,088 Added 121.72%
264,288 $1.44 Million
Q2 2022

Aug 12, 2022

BUY
$3.37 - $7.55 $401,704 - $899,960
119,200 New
119,200 $520,000
Q1 2022

May 13, 2022

SELL
$5.14 - $7.38 $860,045 - $1.23 Million
-167,324 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$2.71 - $5.17 $251,151 - $479,134
-92,676 Reduced 35.64%
167,324 $815,000
Q3 2021

Nov 12, 2021

BUY
$2.28 - $2.95 $272,688 - $352,820
119,600 Added 85.19%
260,000 $718,000
Q2 2021

Aug 13, 2021

BUY
$2.51 - $3.11 $352,403 - $436,644
140,400 New
140,400 $402,000
Q4 2020

Feb 10, 2021

SELL
$2.6 - $5.79 $114,550 - $255,095
-44,058 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$4.34 - $8.28 $58,841 - $112,260
13,558 Added 44.45%
44,058 $217,000
Q2 2020

Aug 13, 2020

BUY
$4.86 - $11.44 $148,230 - $348,920
30,500 New
30,500 $257,000
Q1 2020

May 14, 2020

SELL
$3.31 - $7.15 $93,332 - $201,608
-28,197 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$3.07 - $5.11 $29,788 - $49,582
-9,703 Reduced 25.6%
28,197 $121,000
Q3 2019

Nov 13, 2019

BUY
$3.29 - $8.24 $124,691 - $312,296
37,900 New
37,900 $135,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.